This leads to the observation that the various mutant forms of BCR-ABL result in CML that have unique dynamics under therapy, and that combinations of these inhibitors may be necessary to effectively control a rapidly evolving CML population. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.